000280258 001__ 280258
000280258 005__ 20250904102143.0
000280258 0247_ $$2doi$$a10.1186/s12886-025-04284-5
000280258 0247_ $$2pmid$$apmid:40775308
000280258 037__ $$aDZNE-2025-00936
000280258 041__ $$aEnglish
000280258 082__ $$a610
000280258 1001_ $$aWicherski, Julia$$b0
000280258 245__ $$aAssociation between fluoroquinolones and retinal detachment: insights from a large German health claims-based cohort study.
000280258 260__ $$aLondon$$bBioMed Central$$c2025
000280258 3367_ $$2DRIVER$$aarticle
000280258 3367_ $$2DataCite$$aOutput Types/Journal article
000280258 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1754895022_31915
000280258 3367_ $$2BibTeX$$aARTICLE
000280258 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000280258 3367_ $$00$$2EndNote$$aJournal Article
000280258 520__ $$aReal-world evidence on fluoroquinolone-associated retinal detachment is contradictory. Therefore, we aim to examine the association between newly prescribed fluoroquinolones and the occurrence of retinal detachment with recent data from a large central European country.A cohort study with an active comparator new user design was conducted. Dispensings of fluoroquinolone episodes were compared to a group of reference antibiotic episodes (amoxicillin, amoxicillin clavulanic acid, azithromycin, cefuroxime, cephalexin, clindamycin, sulfamethoxazole-trimethoprim, and doxycycline). Data from one of the largest statutory health insurances in Germany, the AOK, were used to follow up individuals with new antibiotic dispensing during the years 2014-2018 for the occurrence of retinal detachment. Piece-wise exponential additive mixed models adjusted for person-time, age, gender, comorbidities, year, and quarter at index were applied to estimate adjusted hazard ratios (aHR) with corresponding 95% confidence intervals (95% CI).In total, 15,232,585 antibiotic episodes were included in the cohort of which 0.05% episodes had an incident retinal detachment. The covariate-adjusted hazard ratio for fluoroquinolone episodes was 1.01 [0.95;1.08]. Likewise, in the propensity score-matched cohort the covariate-adjusted hazard ratio was 0.99 [0.92;1.07]. Moreover, there was little evidence for differences in age and gender subgroups, by follow-up time, selection of active comparator agent, dosage category, or censoring approach.This large German cohort study found no meaningful real-world evidence for the association between fluoroquinolones and retinal detachment compared to a group of active comparator antibiotics.
000280258 536__ $$0G:(DE-HGF)POF4-354$$a354 - Disease Prevention and Healthy Aging (POF4-354)$$cPOF4-354$$fPOF IV$$x0
000280258 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000280258 650_7 $$2Other$$aActive comparator new user design
000280258 650_7 $$2Other$$aAdministrative cohort
000280258 650_7 $$2Other$$aAdverse drug reactions
000280258 650_7 $$2Other$$aFluoroquinolones
000280258 650_7 $$2Other$$aReal-world data
000280258 650_7 $$2NLM Chemicals$$aFluoroquinolones
000280258 650_7 $$2NLM Chemicals$$aAnti-Bacterial Agents
000280258 650_2 $$2MeSH$$aHumans
000280258 650_2 $$2MeSH$$aFluoroquinolones: adverse effects
000280258 650_2 $$2MeSH$$aGermany: epidemiology
000280258 650_2 $$2MeSH$$aFemale
000280258 650_2 $$2MeSH$$aMale
000280258 650_2 $$2MeSH$$aRetinal Detachment: epidemiology
000280258 650_2 $$2MeSH$$aRetinal Detachment: chemically induced
000280258 650_2 $$2MeSH$$aMiddle Aged
000280258 650_2 $$2MeSH$$aAnti-Bacterial Agents: adverse effects
000280258 650_2 $$2MeSH$$aAged
000280258 650_2 $$2MeSH$$aAdult
000280258 650_2 $$2MeSH$$aIncidence
000280258 650_2 $$2MeSH$$aCohort Studies
000280258 650_2 $$2MeSH$$aRetrospective Studies
000280258 650_2 $$2MeSH$$aFollow-Up Studies
000280258 650_2 $$2MeSH$$aYoung Adult
000280258 7001_ $$0P:(DE-2719)9002192$$aPeltner, Jonas$$b1$$udzne
000280258 7001_ $$aBecker, Cornelia$$b2
000280258 7001_ $$aSchüssel, Katrin$$b3
000280258 7001_ $$aBrückner, Gabriela$$b4
000280258 7001_ $$aSchlotmann, Andreas$$b5
000280258 7001_ $$aSchröder, Helmut$$b6
000280258 7001_ $$aKern, Winfried V$$b7
000280258 7001_ $$0P:(DE-2719)2810511$$aHaenisch, Britta$$b8$$eLast author$$udzne
000280258 773__ $$0PERI:(DE-600)2050436-6$$a10.1186/s12886-025-04284-5$$gVol. 25, no. 1, p. 447$$n1$$p447$$tBMC ophthalmology$$v25$$x1471-2415$$y2025
000280258 8564_ $$uhttps://pub.dzne.de/record/280258/files/DZNE-2025-00936.pdf$$yOpenAccess
000280258 8564_ $$uhttps://pub.dzne.de/record/280258/files/DZNE-2025-00936%20SUP.docx
000280258 8564_ $$uhttps://pub.dzne.de/record/280258/files/DZNE-2025-00936.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000280258 909CO $$ooai:pub.dzne.de:280258$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000280258 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002192$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000280258 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810511$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000280258 9131_ $$0G:(DE-HGF)POF4-354$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Prevention and Healthy Aging$$x0
000280258 9141_ $$y2025
000280258 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000280258 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000280258 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000280258 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC OPHTHALMOL : 2022$$d2025-01-02
000280258 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:34:50Z
000280258 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:34:50Z
000280258 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000280258 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2025-01-02
000280258 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000280258 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-02
000280258 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000280258 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2024-04-10T15:34:50Z
000280258 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2025-01-02
000280258 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000280258 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-02
000280258 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000280258 9201_ $$0I:(DE-2719)1013010$$kAG Hänisch$$lPharmacoepidemiology$$x0
000280258 980__ $$ajournal
000280258 980__ $$aVDB
000280258 980__ $$aUNRESTRICTED
000280258 980__ $$aI:(DE-2719)1013010
000280258 9801_ $$aFullTexts